🇺🇸 FDA
Pipeline program

STAT3 Inhibitor WP1066

NU 21C06

Phase 2 small_molecule active

Quick answer

STAT3 Inhibitor WP1066 for Glioblastoma, IDH-Wildtype is a Phase 2 program (small_molecule) at Moleculin Biotech with 1 ClinicalTrials.gov record(s).

Program details

Company
Moleculin Biotech
Indication
Glioblastoma, IDH-Wildtype
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials